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Catalysis of guanine nucleotide formation from IMP
in the de novo purine synthetic pathway is carried out
by two isoforms of the enzyme inosine monophosphate
dehydrogenase (IMPDH) that are catalytically indistin-
guishable but are encoded by separate genes. In order to
assess the potential for cell type-specific expression of
IMPDH activity, we have characterized the IMPDH type
I gene and identified three major RNA transcripts that
are differentially expressed from three different pro-
moters. A 4.0-kilobase pair (kb) mRNA containing 1.3 kb
of 5*-untranslated region is expressed in activated pe-
ripheral blood lymphocytes and to a far lesser extent in
cultured tumor cell lines. The P1 promoter that regu-
lates the transcription of this mRNA has a high degree of
sequence identity to an Alu repetitive sequence. A tran-
script of 2.7 kb is found in a subset of the tumor cell lines
examined, whereas a 2.5-kb mRNA species is universally
expressed and is the prevalent mRNA in most cell lines
and tissues. The relative strengths of the three promoter
regions and the effects of variable extents of 5*-flanking
sequence on the P3 promoter differ in Jurkat T, as com-
pared with Raji B lymphoid cell lines, demonstrating a
complex cell type-specific transcriptional regulation of
IMPDH type I gene expression.
Inosine 59-monophosphate dehydrogenase (IMPDH;1 EC
1.1.1.205) is an essential, rate-limiting enzyme in the de novo
guanine nucleotide synthetic pathway. It catalyzes the conver-
sion of IMP to XMP at the purine metabolic branch point and
provides sufficient guanine nucleotides for important cellular
processes. The observations that the activity of IMPDH is
tightly linked with both cellular proliferation and transforma-
tion (1–3) have led to an interest in developing IMPDH inhib-
itors for clinical use. Inhibition of IMPDH activity is associated
with depletion of intracellular guanine nucleotide pools and
has been shown both to inhibit cellular proliferation (4, 5) and
to induce cell differentiation (6–9). The specific reversibility by
exogenous guanine of the biologic effects of IMPDH inhibitors
on cell division and differentiation is a unique feature of such
compounds that differentiates them from other inducers of
cellular differentiation. IMPDH inhibitors have also been dem-
onstrated to have considerable efficacy as immunosuppressive
agents (10, 11) and prevent both B and T lymphocyte activation
(12, 13).
Human IMPDH activity is composed of the activities of two
separate but very closely related IMPDH isoenzymes, termed
type I and type II, that are encoded by separate genes located
on chromosomes 7 and 3, respectively (14, 15). The correspond-
ing cDNAs have been isolated (16, 17) and encode two distinct
protein subunits of 56 kDa with 84% sequence identity. The
two IMPDH proteins are tetrameric and are indistinguishable
in their catalytic activities, substrate affinities, and Ki values
for known inhibitors (18–20).
The increased IMPDH activity observed in replicating or
neoplastic cells is largely due to increased expression of the
type II IMPDHmRNA, whereas expression of the type I mRNA
has been thought to be relatively unchanged by cell prolifera-
tion or transformation (21, 22). Conversely, type II mRNA
levels are sharply decreased in response to the induction of cell
differentiation, whereas type I mRNA remains constitutively
expressed (22). A survey of relative IMPDH mRNA levels in
human tissues demonstrated significant differences in the pat-
tern of distribution of the type I transcript, with relatively high
levels in kidney, pancreas, colon, and peripheral blood leuko-
cytes as well as in fetal heart, brain, and kidney (23). Expres-
sion levels of the type II transcript, while generally higher than
type I, were far less variable in different tissue types. These
data support the concept that the two genes are regulated
differently in resting, proliferating, and neoplastic cells and
that these differences may have important consequences for
cellular function.
In view of the important role of IMPDH activity in the
immune response, we have previously studied IMPDH type I
and II expression during T lymphocyte activation and docu-
mented that IMPDH type I mRNA levels increase approxi-
mately 10-fold in response to a variety of stimuli. In addition, T
cell activation results in the appearance of two distinct type I
mRNA transcripts, the larger of which is not readily appreci-
ated in Northern blots of RNA from other cell types (24). This
heterogeneity in IMPDH type I expression has led us to char-
acterize the IMPDH type I gene and compare it with the re-
cently analyzed IMPDH type II gene (25) with the goal of
elucidating possible mechanisms involved in the tissue-specific
expression of the IMPDH type I gene.
MATERIALS AND METHODS
Isolation and Mapping of the IMPDH Type I Gene—The cloning of
the IMPDH type I gene was complicated by the presence in the human
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genome of multiple processed pseudogenes (26). To obtain IMPDH I
genomic clones, a human leukocyte genomic library in the l phage FIX
II vector (provided by Dr. J. Lowe, University of Michigan, Ann Arbor)
was sequentially screened using oligonucleotides complimentary to the
59- and 39-untranslated regions (UTRs) of the type I cDNA (17). Two
positive clones were isolated from the approximately 1.8 3 106 plaques
screened. Clone 1111a was obtained by sequential hybridization to
three oligonucleotides corresponding to the 59-UTR of the cDNA (bp
285 to 2108, 2523 to 2546 and 2448 to 2471, relative to the ATG).
Clone 1711a was obtained using two oligonucleotides corresponding to
the 39-UTR (bp 1614–1637 and 2119–2142). The identity of each clone
was confirmed by hybridization with the cDNA of the entire coding
region. The probes were either end-labeled with [g-32P]ATP (6000 Ci/
mmol; Amersham Corp.) using T4 polynucleotide kinase (Promega,
Madison, WI) or labeled using a random primer labeling kit (Promega)
with [a-32P]dCTP (3000 Ci/mmol; Amersham) to a specific activity of
5–10 3 108 cpm/mg. Hybridizations were performed in a 10% dextran
sulfate, 1% SDS, and 5.8% NaCl solution at 60 °C for 16–24 h, and the
blots were washed twice with 1 3 SSC, 0.2% SDS at room temperature
for 10 min, and once at 50–55 °C for 30 min for oligonucleotide probes.
Hybridization using the cDNA probe was performed at 65 °C and with
a final wash in 0.1 3 SSC, 0.1% SDS at 65 °C for 30 min. Both clones
were digested with the restriction endonuclease SacI and the resulting
fragments subcloned into pGEM7Zf(1) vector. Mapping of the gene was
performed using Southern blot and PCR analysis. The entire coding
region and all exon-intron boundaries were sequenced using the
dideoxynucleotide chain termination method (27) and Sequenase 2.0
(U.S. Biochemical Corp.). For the promoter regions, both automated
double-stranded sequencing and sequencing of single-stranded DNA
were performed in regions with high GC content.
Northern Blot Hybridization—Total cellular RNA was isolated using
TRI-reagent (MRC, Cincinnati, OH). Total cellular RNA (15 or 20 mg)
was electrophoresed on 1% agarose, 2.2 M formaldehyde gels and trans-
ferred to Zeta-Probe GT membranes (Bio-Rad). Prehybridizations were
performed in 1% SDS, 0.1 M NaCl for 1 h at room temperature. Hybrid-
izations were carried out in high efficiency hybridization solution con-
taining 50% formamide (MRC) with 32P-labeled probe at 2–3 3 106
cpm/ml at 42 °C for 24–48 h. Oligonucleotide probes were washed in
1 3 SSC, 0.2% SDS at 50 °C for 30 min, the p190 probe was washed in
0.1 3 SSC, 0.1% SDS at 50–60 °C for 30 min, and the p700 and 1.5-kb
cDNA probes were washed in 0.1 3 SSC, 0.1% SDS at 65 °C for 30 min.
Human peripheral blood lymphocytes (PBLs) were isolated from
buffy coats obtained from the American Red Cross (Charlotte, NC)
using Histopaque-1077 (Sigma) gradient centrifugation. Monocytes and
macrophages were removed using the adherence method (28). Purified
PBLs were incubated at a concentration of 1.5 3 106/ml in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum
(Life Technologies, Inc., Grand Island, NY), 100 units/ml penicillin, and
100 mg/ml streptomycin for 24 h in the presence or absence of 10 ng/ml
of phorbol 12-myristate 13-acetate and 250 ng/ml of ionomycin (Calbio-
chem). The extent of lymphocyte activation was monitored by meas-
uring [3H]thymidine incorporation into DNA at 24 and 48 h of
activation.
Primer Extension—An oligonucleotide primer complimentary to
bases 73–99 in exon 1 was end-labeled with [g-32P]ATP using T4
polynucleotide kinase. Probe (1 3 105 cpm) was mixed with 20 mg of
total RNA from Jurkat and Raji cells or tRNA as a control and precip-
itated. Annealing was performed in 20 ml of 1 3 avian myeloblastosis
virus reverse transcription buffer (Promega) and incubated sequen-
tially at 75 °C for 15 min and 60 °C for 30 min and slowly cooled to
40 °C. Extension was performed in the presence of 20 units of avian
myeloblastosis virus reverse transcriptase (Promega), 1 mM dNTPs, and
10 units of RNasin (Promega) at 42 °C for 90 min. The mixture was then
digested with 20 mg/ml DNase-free RNase (Boehringer Mannheim) at
37 °C for 20 min followed by phenol/chloroform extraction and ethanol
precipitation. The resulting products were resuspended in 5 ml of gel
loading buffer, and 3 ml was analyzed on a denaturing 8 M urea, 6%
polyacrylamide gel. The gel was dried and autoradiographed at 270 °C
for 2 days.
Ribonuclease Protection Assay—A pGEM-320 construct, containing
genomic DNA extending 280 bp upstream and 45 bp downstream of the
ATG translation initiation site was used for RNase protection assays
using the Ribonuclease Protection Assay kit (Ambion, Austin, TX). The
construct was digested with the restriction endonuclease BglI, gener-
ating a 1.6-kb fragment containing the SP6 promoter and 115 bp 59 to
the ATG initiation codon. This fragment was gel-purified and tran-
scribed in vitro using SP6 RNA polymerase (Promega) to generate a
[32P]CTP-labeled 235-bp antisense RNA probe. The labeled probe (5 3
105 cpm) was added to 30 mg of total RNA from Jurkat and Raji cells and
30 mg of tRNA, and ethanol-precipitated. Hybridizations were per-
formed in 20 ml of hybridization buffer at 45 °C for 20 h, and samples
were digested with a RNase A and T mixture (1:100 dilution) at 37 °C
for 30 min and precipitated in the presence of 2 mg of tRNA. The pellets
were resuspended in 5 ml of gel loading buffer, and 3 ml was analyzed on
6% denaturing polyacrylamide gels.
Plasmid Constructs—The P1 and the P2 promoter regions were ob-
tained by PCR using the following primers: 32F (59-TGTAATCCCAG-
CATTTTGGGA-39) and 33R (59-GCTCTGTCGCCCAGGCTGGAGT-39)
for the P1 region; 7F (59-TTCTTTCCAGTCCCACCCGTGTAG-39) and
18R (59-TGGCGTTTCGGGAAGTTA-39) for the P2 region (see Fig. 3).
The amplified regions were cloned into the PCRTM II vector (Invitrogen,
San Diego, CA) and subcloned into the HindIII site of the pCAT-Basic
vector (pCATB) in 593 39 orientation upstream of the chloramphenicol
acetyltransferase (CAT) gene. Fragments of 0.4, 0.7, 1.4, and 2.7 kb 59
to exon 1 were isolated by restriction enzyme digestions, as indicated in
Fig. 6, gel-purified, and subcloned into the SalI site of pCATB. The
pCATB/0.7 construct is designated as P3. The orientation of each con-
struct was verified by direct sequencing.
Transient Transfection and CAT Assays—Plasmid DNA used for
transfection experiments was prepared using QIAGEN columns
(Chatsworth, CA), and the DNA was quantitated by both spectropho-
tometry and ethidium bromide staining. To determine the transcrip-
tional activity of the putative promoters, 20 mg of each construct was
added to 107 exponentially growing Jurkat or Raji lymphoblasts in a
total volume of 500 ml of serum-free RPMI 1640 medium. Electropora-
tions were performed using a Bio-Rad Gene Pulser set at 250 V and 960
microfarads. Cells were plated in 20 ml of RPMI 1640 medium contain-
ing 10% fetal bovine serum, 100 units/ml of penicillin, and 100 mg/ml of
streptomycin and cultured for 44–48 h at 37 °C in a humidified atmo-
sphere in the presence of 5% CO2. A b-galactosidase plasmid under
control of the b-actin promoter (pbAc-lacZ) (kindly provided by Lorraine
Gudas, Cornell University) was used in each experiment to control for
transfection efficiency. After harvesting, cells were washed twice in cold
phosphate-buffered saline and extracted in 150 ml of 0.25 M Tris-HCl
(pH 8.0) with three cycles of freeze-thawing. After centrifugation at
14,000 3 g for 5 min, supernatants were used for protein quantitation
using the Micro BCA protein assay reagent kit (Pierce) and for assay of
b-galactosidase activity by a modification of a published technique (29)
using chlorophenolred b-D-galactopyranoside (Boehringer Mannheim)
as a substrate. For CAT assays, aliquots of supernatant were heated at
60 °C for 10 min followed by centrifugation at 14,000 3 g for 5 min, and
50 ml of supernatant were then incubated with 0.125 mCi of [14C]chlor-
FIG. 1. Schema and partial restric-
tion map of the human IMPDH type I
gene. Exons are represented by boxes and
numbered at the bottom. The shaded box
(A9) indicates sequences between the 59-
end of the published cDNA (exon A) and
the upstream transcription start site de-
termined in the present study. P1, P2,
and P3 refer to the locations of the three
promoter regions. The locations of probes
p700 and p190 used in Northern hybrid-
izations are also shown. Exons are num-
bered according to their position in the
coding sequence, with exon 14 containing
713 bp of 39-untranslated sequence.
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amphenicol (Amersham) and 25 mg of n-butyryl coenzyme A (Sigma) for
2–6 h, depending on the transfection efficiency of each experiment.
Reactions were extracted with xylenes and counted in a Beckman
scintillation counter (model LS 7800; Beckman, Irvine, CA). CAT activ-
ity was normalized for extract protein concentration and calculated as
cpm/mg/min of assay.
RESULTS
Cloning and Mapping of the IMPDH Type I Gene—Two
phage clones (1111a (14 kb) and 1711a (13 kb)) were isolated
that overlap by 3.6 kb in the intragenic region and extend
approximately 6.3 kb 59 and 4.7 kb 39 from the ends of the
coding region. A physical map of the gene was established
using a combination of restriction mapping, PCR, and sequence
analysis of the two genomic clones (Fig. 1). The entire IMPDH
type I gene is approximately 18 kb in length. According to the
published cDNA sequence (17), the 59-UTR is composed of 600
bp, which we have designated as exons A-C in Fig. 1. Exon A9
is the region between exon A and an upstream transcription
initiation site described below. The coding region of the gene
contains 14 exons, the last of which includes 713 bp of 39-UTR.
All exon-intron boundaries contain the canonical splice donor
(AG) and acceptor (GT) consensus sequences, with the excep-
tion of a GC splice acceptor site at exon 4. Within the coding
region, 16 bases differ from the published cDNA sequence (17).
Six of these base changes result in amino acid differences: bp 86
(A 3 G; aspartic acid 3 glycine); 327 (C 3 G; asparagine 3
lysine); 819 (C 3 G; phenylalanine 3 leucine); 820 (C 3 G;
histidine 3 aspartic acid); 1255 (C 3 G; proline 3 alanine);
and 1489 (C 3 G; proline 3 alanine).
Comparison of the Genomic Structures of the IMPDH Type I
and II Genes—The type I gene is significantly larger than the
5.8-kb type II gene (25). However, as shown in Table I, the
exons of the coding region are identical in size and contain the
same amino acids at each exon boundary with the exception of
an isoleucine 3 valine substitution at the exon 5/6 boundary.
The type I gene contains substantially larger introns, seven of
which are over 1 kb in length, and has approximately 1.3 kb of
59-UTR and 713 bp of 39-UTR, as compared with 50 and 53 bp
in the type II gene, respectively (16, 25). In addition, nine ATG
codons are present in the 59-UTR of the type I gene.
Analysis of IMPDH Type I Transcripts—Previous studies
have demonstrated two IMPDH type I mRNA species of ap-
proximately 3 and 4 kb on Northern blot analysis of RNA from
peripheral blood T lymphocytes (24). RNase protection assays
suggested that the larger mRNA species of 4 kb contained
additional 59 or 39 sequences, since the coding regions of both
mRNA species were identical. In order to determine the com-
position of these mRNAs, Northern blot hybridization was per-
formed on total cellular RNA isolated from resting or activated
human PBLs using probes corresponding to different exons.
Using a cDNA probe corresponding to the coding region (exons
1–14), the expression of both a 4- and a 2.5-kb RNA species, as
accurately assessed using RNA markers, was markedly in-
duced as a result of phorbol 12-myristate 13-acetate plus iono-
mycin treatment of PBLs (Fig. 2A, lanes 1 and 2). When a
700-bp probe encompassing 500 bp in exon A9 and 200 bp in
exon A (p700; Fig. 2A, lanes 3 and 4) and a 190-bp probe
spanning the region from exon B to exon C (p190; Fig. 2A, lanes
5 and 6) were used as probes, only the 4-kb mRNA was ob-
served, indicating that this mRNA species originates upstream
of the 2.5-kb mRNA and contains a significantly longer 59-UTR.
In contrast, both mRNA species were readily detected by two
oligonucleotides derived from exon 1 sequence (Fig. 2A, lanes 7
FIG. 2. Differential expression of three IMPDH type I mRNA
species. A, Northern blot analysis of IMPDH type I mRNA was per-
formed on 15 mg of total cellular RNA from resting (lanes 1, 3, 5, and 7)
or activated (lanes 2, 4, 6, and 8) PBLs using probes corresponding to
different exons as described under ‘‘Results.’’ B, 20 mg of total RNA from
K562 (lane 1), U937 (lane 2), KT-1 (lane 3), MOLT-4 (lane 4), Jurkat
(lane 5), MGL-8 (lane 6), Nalm-6 (lane 7), Raji (lane 8), and H1437 (lane
9) cell lines were hybridized with the p190 probe. (C). The blot used in
B was rehybridized with an IMPDH type I cDNA coding region probe.
D, the blot used in B was rehybridized with a 28 S rRNA probe. The
three IMPDH type I mRNA species (2.5, 2.7, and 4 kb) are indicated by
arrows.
TABLE I
Comparison of exon and intron sizes for the IMPDH type I and II genes
Exons
A 1 A9 B C 1 2 3 4 5 6 7 8 9 10 11 12 13 14
IMPDH type I ;1200 44 64 99 49 102 75 207 88 200 91 96 144 145 144 84 735
IMPDH type II 148 49 102 75 207 88 200 91 96 144 145 144 84 75
Introns
A B C 1 2 3 4 5 6 7 8 9 10 11 12 13
IMPDH type I 265 88 ;3200 ;2000 ;2300 137 278 149 ;1500 ;1400 236 ;1300 94 288 93 ;1200
IMPDH type II 445 225 107 327 657 73 77 99 1065 83 94 80 89
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and 8). Northern blot analysis was also performed on total
cellular RNA isolated from nine tumor or transformed cell
lines: an erythroleukemia line, K562; a monocytic leukemia
line, U937; three T cell leukemia cell lines, KT-1, MOLT-4, and
Jurkat; three B lymphoblast cell lines, MGL-8, Nalm-6, and
Raji; and a lung cancer cell line, H1437 (Fig. 2B, lanes 1–9).
Upon hybridization with the p190 probe, as shown in Fig. 2B,
a third RNA species of approximately 2.7 kb was detected with
relatively high abundance in U937, Jurkat, and H1437 cells
but was absent in MGL-8 and Raji cells, as well as in PBLs. In
order to confirm that this 2.7-kb band is not identical to the
major 2.5-kb mRNA transcript, the blot was rehybridized with
the 1.5-kb cDNA coding region probe. As shown in Fig. 2C, all
of the cell lines demonstrated an abundant 2.5-kb transcript,
with U937 and Raji cells having the highest level of expression
after normalized for 28 S ribosomal RNA (Fig. 2D). These
results clearly indicate the existence of three IMPDH type I
RNA transcripts that differ at their 59 termini.
Identification and Functional Analysis of the IMPDH Type I
Promoter Regions—To study the elements involved in the reg-
ulation of IMPDH type I transcription, approximately 2.7 kb 59
of exon C and 700 bp 59 of exon 1 were sequenced. Three regions
were identified as putative promoter regions based on sequence
analysis; each contains a number of putative transcription
factor binding sites, and we have designated them as P1, P2,
and P3, respectively (Fig. 1). As shown in Fig. 3A, the P1 region
encompasses 245 bp, as defined by PCR primers 32F and 33R,
is located immediately 59 to exon A9, and includes five Sp1 and
two AP2 sites, one serum response element site, one NFkB site
that overlaps with a SIF consensus binding sequences, and one
ELP site. There is no TATA box in this region, although a
consensus sequence for transcription factor IID is present. Of
interest is the fact that this sequence is 95% identical to the
catarrhine-specific (CS) Alu repetitive sequence found widely
throughout the genome (30), although the consensus Alu se-
quence does not function as a promoter in similar transfection
experiments (data not shown). A highly AT-rich region of 52 bp,
containing four AAAAT repeats plus stretches of A nucleotides
separated by a single T or C is located 39 to the P1 element.
Primer extension analysis using RNA from both resting and
activated PBLs demonstrated two possible transcription initi-
ation sites downstream of the P1 promoter, as indicated in Fig.
3A. Ribonuclease protection analysis detected a single band
corresponding to the more 39 initiation site, although the
absence of a longer protected fragment could have resulted
from nonspecific cleavage by RNase A of the A-rich sequence
(data not shown).
The P2 region (Fig. 3B), 595 bp in length, is located 118 bp 59
to exon B, and contains 73% G 1 C residues, a number of Sp1
and AP2 binding sites, a PuF consensus binding site, and an
Ets-1 consensus binding site. A putative transcription initia-
tion site located 134 bp 59 to exon B was determined by primer
extension analysis using a primer located in exon C. The P3
region (Fig. 3C), 671 bp in length, is located immediately 59 to
exon 1 and also has a high G 1 C content of 73%. This region
contains, in addition to a number of potential Sp1 and AP2
binding sites, three Egr-1 sites (two of them overlapping with
Egr-2 sites), three PuF, two serum response elements, and a
site for CCAAT/enhancer-binding protein (C/EBP), a cAMP-
response element (CRE), and a CCAAT binding site. Primer
extension was performed using total RNA isolated from Jurkat
FIG. 3. Sequences of the IMPDH type I P1 (A), P2 (B), and P3
(C) promoters. The three putative promoter regions used to assay
CAT activity are shown in boldface type. Putative transcription factor
binding sites based on consensus sequences are indicated by underlin-
ing. The primers (32F, 33R, 7F, and 18R) used for PCR are indicated.
Transcription initiation sites based on primer extension analysis and
confirmed by RNase protection assays are shown by arrows. The tran-
scription start sites determined by primer extension only are shown by
arrows with parenthesis. The P3 sequence is numbered relative to the A
of the ATG start codon (11) in exon 1.
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and Raji cell lines and an oligonucleotide corresponding to the
exon 1 region. Two transcription initiation sites were identified
40 bp (major) and 24 bp (minor) 59 to the ATG initiation codon
(Fig. 4A), and these results were confirmed by a ribonuclease
protection assay in which two corresponding protected frag-
ments were detected using RNA from Jurkat and Raji cells but
not with the tRNA control (Fig. 4B). The greater intensity of
the primer-extended bands and RNase-protected bands in Raji
cells is consistent with the higher levels of the 2.5-kb mRNA in
this cell line (Fig. 2C).
Functional studies of the P1, P2, and P3 regions were per-
formed using transient transfection assays with CAT reporter
gene constructs (Fig. 5). In both Jurkat and Raji cell lines, the
activity of the P3 region is greater than that of the P1 and P2
regions. In the Jurkat T cells, constructs containing P1 or P2
result in an approximate 20-fold increase in CAT activity over
the values obtained with the pCATB vector alone. In the Raji B
cell line, in contrast, the P1 and P2 constructs resulted in a
1.2–6-fold increase in CAT activity, although P3 retained a
level of promoter activity equivalent to that found in Jurkat
cells. In order to define the P3 promoter region further, addi-
tional constructs containing variable regions 59 to exon 1 were
compared for their ability to promote transcription in Jurkat
and Raji cells (Fig. 6). In Jurkat cells (Fig. 6A), the construct
pCATB/0.7, containing a 671-bp ApaI-NotI fragment of P3, had
the strongest promoter activity, while the activity of construct
pCATB/2.7, containing additional 59 sequences, is only about
15–20% that of the pCATB/0.7 construct. This profile differs
markedly from that in Raji cells (Fig. 6B), where pCATB/2.7
has approximately 6-fold higher promoter activity than the
pCATB/0.7 construct. These results strongly suggest that there
are elements 59 to the P3 region that may regulate transcrip-
tion from this promoter in a cell type-specific fashion.
Transcriptional activity from the P3 element (pCATB/0.7)
was compared with that from the 461-bp promoter for the
IMPDH type II gene (25). CAT activity obtained with the type
II promoter was 70-fold greater than that with the P3 promoter
in both Jurkat and Raji cells (data not shown). This result is
consistent with the observation that the expression of the type
II IMPDH gene at the mRNA level is significantly higher than
that of the type I gene in most tissues and cell lines tested (23)
and suggests that transcriptional regulation may play a major
role in determining the relative levels of expression of these
two genes.
DISCUSSION
The co-existence in mammalian cells of two IMPDH genes
with striking conservation of amino acid identity and catalytic
function argues that each subserves an important and nonover-
lapping function in cellular physiology or development. Since
the expression of the IMPDH type II gene at the mRNA level
has correlated more directly with cellular proliferation and
transformation, it has been assumed that the IMPDH type I
gene might provide a constitutive and noninducible level of
guanine nucleotide biosynthesis (21, 22). However, the striking
increase in IMPDH type I mRNA expression with T lymphocyte
activation, the presence of a second mRNA transcript in these
cells, and the variability in IMPDH type I gene expression in
FIG. 4. Determination of the tran-
scription initiation site for the major
2.5-kb transcript. A, primer extension
analysis was performed using an oligonu-
cleotide primer located in exon 1 and total
cellular RNA from Jurkat or Raji cells or
tRNA. The major and minor bands are
indicated by arrows. The sequence ob-
tained using the same oligonucleotide
primer is shown on the right. The asterisk
indicates the major transcription initia-
tion site. B, ribonuclease protection assay
performed with RNA from Jurkat, Raji
cells and tRNA, and a 235-bp RNA probe
as described under “Materials and Meth-
ods.” The two major protected bands not
seen in the tRNA lane are indicated by
arrows. DNA markers in bp are shown.
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different tissues all support the concept that the regulation of
expression of this gene may play a more significant role in
cellular responses than had previously been appreciated. It was
for this reason that a study of the structural characteristics of
the IMPDH type I gene was undertaken.
The finding that the IMPDH type I gene retains the same
exon structure as the smaller IMPDH type II gene argues for
an early gene duplication event, while the preservation of the
two functional genes throughout vertebrate evolution (26) sup-
ports an essential role for each. There are other striking exam-
ples of multigene families that account for tissue-specific dif-
ferences in the expression of human enzymes important for
nucleotide metabolism. Phosphoribosyl pyrophosphate synthe-
tase (EC 2.7.6.1) catalyzes the synthesis of phosphoribosyl py-
rophosphate, the primary precursor of the ribose monophos-
phate moiety of all nucleotides and a critical regulator of de
novo purine and pyrimidine biosynthesis (31). Two isoforms,
phosphoribosylpyrophosphate synthetase subunits I and II, are
encoded by distinct genes (PRPS1 and PRPS2) located on dif-
ferent regions of the X chromosome (32), and are expressed in
a tissue-specific manner (33). A third phosphoribosyl pyrophos-
phate synthetase gene encoding a testes-specific isoform is
autosomal in location (34). The tissue specificity of the expres-
sion of these genes has been attributed to the differences in
59-flanking sequences and corresponding differences in tran-
scriptional activity (35). Similarly, there are four isoforms of
AMP deaminase (EC 3.5.4.6) encoded by three AMP deaminase
genes (36). Recent studies have demonstrated alternative tran-
scripts from the AMPD2 gene that are expressed in a mutually
exclusive pattern and that confer variable N-terminal exten-
sions to their encoded peptides (37), while multiple RNA tran-
scripts from the AMPD3 gene are regulated by three distinct
promoters in the 59-flanking region (38). It appears from these
and other examples that the tissue-, development-, and growth-
regulated expressions of genes encoding enzymes essential for
nucleotide metabolism may have important consequences for
the development and survival of the organism as a whole.
The regulation of IMPDH type II gene expression has been
studied in detail in resting and activated T lymphocytes and
has been shown to be transcriptional in nature (25).2 Stimula-
tion of T cells with phytohemagglutinin plus interleukin-2 in-
duces increased transcription from a single core promoter re-
gion that contains tandem cAMP-response element binding
sites, an Sp1 site, and a novel palindromic octamer sequence.2
In contrast, the regulation of IMPDH type I expression is more
complex and is governed by the presence of three alternative
promoters in the 59-flanking region (Fig. 7). The P1 promoter
gives rise to a 4.0-kb transcript that is primarily found in PBLs,
and expression of this transcript increases markedly with T cell
activation, as does expression of the 2.5-kb mRNA from the
more generally utilized P3 promoter. The presence of an NFkB
consensus binding site within the P1 region may be of direct
relevance to this observation, since NFkB is involved in medi-
ating the transcription of a number of genes following B and T
lymphocyte activation, as well as in response to inflammatory
cytokines (40). The 10-fold increase in IMPDH enzymatic ac-
tivity and consequent increase in guanine nucleotide biosyn-
thesis that occurs during T lymphocyte activation (5, 24) are
prerequisites that enable these cells to enter S phase, and these
events appear to be extremely important in T cell biological
responses (13, 41). Although the relative contributions of
IMPDH type I and II proteins to this increase in activity have
been difficult to determine, given their high degree of amino
acid identity, it is possible that the appropriate regulation of
IMPDH type I gene expression is essential for the T cell mito-
genic response.
The long 59-UTR found initially in the published cDNA se-
quence (17) and demonstrated more fully as a result of our
genomic characterization may play an additional role in regu-
lating IMPDH type I activity. In the 4-kb IMPDH type I RNA
transcript, there are 1.3 kb of sequence 59 to the known trans-
lation start site that include nine AUG codons followed by open
reading frames encoding putative peptides ranging from 3 to 85
amino acids. Two of these upstream AUG codons are in frame
with the initiation codon for methionine in exon 1, raising the
possibility that IMPDH type I isoforms with an additional 85 or
8 amino acids could be generated. Although we have been
unable to identify size variants of IMPDH type I protein in
Western blots of activated PBL extracts (data not shown), it is
certainly possible that protein with N-terminal extensions
2 A. G. Zimmermann, K. L. Wright, K. L., J. P.-Y. Ting, and B. S.
Mitchell, submitted for publication.
FIG. 5. Transcriptional activity of the P1, P2, and P3 promot-
ers in Jurkat (A) and Raji (B) lymphoid cells. Cells were tran-
siently transfected with plasmids containing the P1, P2, or P3 regions,
as described under “Materials and Methods,” and assayed for CAT
activity. Relative CAT activity refers to -fold increase over values ob-
tained by pCATB vector control, and bars represent the mean 6 S.D. of
four (Jurkat) and six (Raji) transfections performed in duplicate.
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could be synthesized. In addition, there is increasing evidence
that 59-UTR sequences longer than several hundred nucleo-
tides may, as a consequence of their propensity to form second-
ary structure, regulate gene expression at the translational
level (42). Although the presence of multiple AUG translation
start codons have been shown to attenuate translation (43),
there are also precedents for positive regulation, as in the
induction of yeast GCN4 translation in response to amino acid
availability (44) and in the Rous sarcoma virus RNA transla-
tion (45). Furthermore, tissue specificity of expression may be
dictated by translational control mediated through this region
(46, 47). Thus, although the 4-kb transcript is present in rela-
tively low abundance in the tissues other than PBLs that have
been surveyed to date, we cannot preclude a significant biologic
role for this RNA species in regulating IMPDH type I enzyme
synthesis.
The P2 promoter is GC-rich and appears to regulate the
expression of a 2.7-kb transcript in a manner that is dispropor-
tionate to the expression of the 2.5-kb transcript in several
cultured cell lines. Since this band can only be clearly dissoci-
ated from the 2.5-kb transcript by differential hybridization to
the p190 probe, it is difficult to determine the extent to which
FIG. 6. Delineation of P3 promoter activity in deletion constructs. Jurkat (A) and Raji (B) cells were transfected with CAT constructs
containing regions 0.4, 0.7, 1.4, and 2.7 kb 59 to the ATG, as outlined under “Materials and Methods.” CAT activity is expressed relative to the value
obtained with the pCATB/0.7 construct, which has been set as 100. Data represent the mean 6 S.D. of three experiments performed in duplicate.
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it is present in the tissues that have been studied to date (23).
Although the structure of the P2 region does not appear to
contain transcription factor binding sites that are highly tis-
sue-specific in nature, the observation that the relative expres-
sion of CAT from a reporter construct containing 595 bp of
sequence from this region is significantly higher in Jurkat that
in Raji cells, together with the presence of the 2.7 transcript in
the former but not the latter cell line, would support the con-
cept of tissue-specific expression.
The P3 promoter accounts for the major 2.5-kb transcript
and contains a large number of Sp1 and AP2 binding sites that
may be responsible for the basal expression of this gene. The
presence of several NGFI-A/Egr-1 sites in close proximity to the
transcription initiation sites offers one potential explanation
for the up-regulation of the 2.5-kb mRNA with T cell activation,
since Egr-1 is a zinc finger protein induced following interleu-
kin-2 stimulation of T lymphocytes that appears to be impor-
tant for subsequent cellular proliferation (48). In addition, the
presence of three consensus binding sites for PuF further up-
stream raises the possibility that NM23.H2, a product of one of
two NM23 genes, could be involved in IMPDH I regulation.
NM23.H2 is one of two subunits of nucleoside diphosphate
kinase (EC 2.7.4.6), an enzyme that is important both in main-
taining nucleoside triphosphate pools (49, 50) and in activating
GTP-dependent proteins (51, 52). NM23.H2 has been shown to
function as a transcription factor for the c-myc gene (53) and,
together with NM23.H1, to be up-regulated in human PBLs
following phytohemagglutinin stimulation with a time course
that is consistent with the increase in IMPDH type I mRNA
expression (24, 54). Whether or not these specific binding sites
are important for the up-regulation of the 2.5-kb transcript in
PBLs remains to be determined.
Of additional interest with regard to the P3 promoter region
is the differential expression of CAT constructs containing vari-
able amounts of 59 sequence extending as far as the SacI site 39
to exon C (Fig. 1). Tissue specificity is evident in that maximal
activity in Jurkat T cells is obtained with the 700-bp region 59
to the ATG that includes the PuF and Egr-1 sites, whereas
6-fold greater relative activity is found in Raji cells when an
additional 2 kb of upstream sequence is included in the con-
struct. This observation again underscores the potential com-
plexity of IMPDH type I gene transcriptional regulation. In
contrast to the concept that the expression of IMPDH type I
gene does not vary as a function of cell proliferation or trans-
formation, our results support the view that the IMPDH type I
gene is subject to differential regulation at the transcriptional
level from three promoter regions in a highly tissue- or cell-
specific manner. The list of enzymes whose expression is reg-
ulated by multiple promoters and alternative processing at the
59-end, as well as by the presence of multiple genes with vary-
ing regulatory sequences encoding nearly identical proteins, is
growing steadily (39). The biological roles of IMPDH type I that
require this diversity of regulation remain to be determined.
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